<SEC-DOCUMENT>0000950170-21-000607.txt : 20210729
<SEC-HEADER>0000950170-21-000607.hdr.sgml : 20210729
<ACCEPTANCE-DATETIME>20210729160113
ACCESSION NUMBER:		0000950170-21-000607
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210729
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210729
DATE AS OF CHANGE:		20210729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alector, Inc.
		CENTRAL INDEX KEY:			0001653087
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				462702363
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38792
		FILM NUMBER:		211127289

	BUSINESS ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD., SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		415-231-5660

	MAIL ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD., SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alector LLC
		DATE OF NAME CHANGE:	20150915
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>alec-20210729.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-07-29T13:35:13.1988+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:alec="http://alector.com/20210729">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_49c01743-ec62-4852-9541-dd9e5294637e" name="dei:AmendmentFlag" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57">false</ix:nonNumeric><ix:nonNumeric id="F_7172732d-d8d2-4293-8b7c-cd997a97f281" name="dei:EntityCentralIndexKey" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57">0001653087</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="alec-20210729.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-29</xbrli:startDate><xbrli:endDate>2021-07-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.250pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57e34499-e102-4ab6-a3e1-f421cb33cf0d" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:DocumentType"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c21b7b8-bb41-4106-af63-7742a446f0c3" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">July 29, 2021</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b331cc29-0652-47a5-9cba-fb915a041955" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:EntityRegistrantName"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:24.0pt;font-family:Times New Roman;">Alector, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb97b522-68ed-4353-a64a-57c3853df4a9" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1dad3607-97c5-4132-a8ce-209c5eb90d48" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:EntityFileNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-38792</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31dc34bb-dd31-4179-b9a0-adc4da5dc08b" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:EntityTaxIdentificationNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">82-2933343</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36e832b3-e2b4-4ae0-9318-071f207ad13a" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:EntityAddressAddressLine1"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">131 Oyster Point Blvd.</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_feea7dd1-f54e-4ba2-b3d9-e3bfde97c952" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:EntityAddressAddressLine2"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Suite 600</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4975b273-9684-4f29-afd4-9fa6ebad82d1" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:EntityAddressCityOrTown"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">South San Francisco</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7f68c3e-37b2-4136-a2ec-7ab7b11e5f93" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75e49c21-208f-4ce3-958b-b663d66645c1" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:EntityAddressPostalZipCode"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">94080</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1be4cb6-a72a-4aac-8465-50cb3ae60cc4" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:CityAreaCode"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(415)</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_782b6cb3-d2ad-4bad-b0b3-0f70b77c22c7" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:LocalPhoneNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">231-5660</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6e704d6-ab11-48f7-bc81-f24709c46776" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c949abb3-d66d-4979-af53-14a484194d63" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dedc8c92-47a8-4289-a1d6-1eb87579d2da" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a076777-2535-4add-9779-b9008b12a105" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.011pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.011pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bc0796a-5dc1-4ff3-9a54-602d6e71a66e" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:Security12bTitle"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common Stock</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f89ca3b6-930f-4629-bf6e-9175184be3cd" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:TradingSymbol"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ALEC</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43b02bf9-f009-4af9-ba1a-4af9733f639a" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The NASDAQ Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_1c978d3e-5280-4a60-ab27-5fb5546c0818" contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 29, 2021, Alector, Inc. issued a press release announcing data from its Phase 2 trial of AL001 patients with FTD (N=12) at the 2021 Alzheimer&#x2019;s Association International Conference held on July 26, 2021 through July30, 2021. A copy of that press release is attached as Exhibit 99.1 and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information furnished in this Item 8.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be &#x201c;filed&#x201d; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of such section, nor shall such information &#160;be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">d) Exhibits</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.741%;"></td>
    <td style="width:88.259%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="alec-20210729ex99_1.htm"><span style="color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.0%;"></td>
    <td style="width:44.0%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:46.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ALECTOR, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 29, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/&#160;Arnon Rosenthal</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Arnon Rosenthal, Ph.D.<br />Co-founder and Chief Executive Officer<br />(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>alec-20210729ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img60799751_0.jpg" alt="img60799751_0.jpg" style="width:154px;height:41px;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">		</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;">Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;font-style:italic;">AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:11.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;font-style:italic;">Treatment with AL001 Slowed Clinical Progression by 47% Based on the CDR</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:7.37pt;font-family:Arial;font-style:italic;">&#174;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;font-style:italic;"> plus NACC FTLD-SB Scale Relative to GENFI2 Matched Control Cohort</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;font-style:italic;">Consistent Trends toward Normalization or Stabilization in <br>Multiple Disease Biomarkers Observed with AL001 Treatment</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Arial;font-style:italic;">Data from Phase 2 Study Presented at Alzheimer&#x2019;s Association International Conference; Management to Host Webcast to Review Results Today at 1:00 p.m. ET</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:9.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Denver, CO,&#160;July 29, 2021</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;-- Alector, Inc.&#160;(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented promising results from the company&#x2019;s INFRONT-2 Phase 2 clinical trial of AL001 at the Alzheimer&#x2019;s Association International Conference (AAIC 2021).  AL001 is initially being developed for the treatment of adults at risk for or with symptomatic frontotemporal dementia due to a progranulin gene mutation (FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">).  AL001 is a potential first-in-class monoclonal antibody designed to elevate progranulin, a key regulator of immune activity in the brain.  Decreased progranulin levels due to genetic mutations are a known cause of frontotemporal dementia (FTD), a rare, rapidly progressing neurodegenerative disease that is the most common form of dementia for people under the age of 60.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Data presented today focused on up to twelve symptomatic FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> patients treated over twelve months in an open-label study designed to assess safety, pharmacokinetics and pharmacodynamics, exploratory biomarkers and efficacy.  AL001 showed a favorable safety profile and rapidly restored progranulin levels to normal ranges in both plasma and cerebrospinal fluid (CSF) for the duration of treatment.  While the INFRONT-2 Phase 2 study was not designed to demonstrate clinical benefit, clinical outcome assessments using the CDR</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Arial;">&#174;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> plus NACC-FTLD-SB scale found that AL001 treatment slowed clinical progression by 47% compared to a matched control cohort of participants from the Genetic FTD Initiative (GENFI2)</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Arial;">(1)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">.  Additionally, multiple disease-relevant biomarkers of lysosomal function, complement activation and neuronal health trended toward normalization or remained stable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201c;Though this is a small open-label study, the totality of the data presented from the INFRONT-2 Phase 2 study paint an encouraging picture of AL001&#x2019;s potential to slow disease progression in patients with FTD, a devastating disease for which there are currently no approved treatment options,&#x201d; said Robert Paul, M.D., Ph.D., Alector&#x2019;s Chief Medical Officer.  &#x201c;Chronic treatment with AL001 demonstrated durable, on-target activity with a complete reversal of the progranulin deficiency that is causing disease.  The effect of AL001 treatment on clinical disease progression, and consistent improvements observed across diverse biomarkers, strengthen our confidence that AL001 is working as designed.  We look forward to building upon these data in our Phase 3 study of AL001 in FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> mutation carriers and other planned studies in patient populations in which progranulin deficiencies are a known risk factor.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Alector is actively enrolling the INFRONT-3 Phase 3 pivotal clinical study of AL001 in at-risk and symptomatic carriers of the progranulin mutation causative of FTD.  The global randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of AL001 in inhibiting disease progression with the primary endpoint, CDR</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Arial;font-style:italic;">&#174;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> plus NACC-FTLD-SB scale.  AL001 is also being studied in FTD patients with a </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">C9orf72</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> mutation, with plans to begin testing AL001 in </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">C9orf72</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> amyotrophic lateral sclerosis (ALS) in the second half of 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Arial;font-style:italic;">Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 <br>for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Calibri;">Page </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Calibri;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">INFRONT-2 Phase 2 Clinical Trial Results</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">The open-label INFRONT-2 Phase 2 study was designed primarily to assess the safety and tolerability of chronic dosing of AL001 over 96 weeks.  INFRONT-2 included three cohorts of FTD patients: asymptomatic FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> patients, symptomatic FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> patients and FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">C9orf72</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> patients.  Biomarker and clinical results presented today focused on the symptomatic FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> cohort and included 12-month data for up to twelve patients who received 60mg/kg of AL001 every four weeks.  As of the data cut, nine FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">patients had completed twelve months of treatment, and between seven and nine patients were able to complete all assessments.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Safety data was reported across all three cohorts (N=27) who received a median of 15 doses of AL001.  AL001 showed a favorable safety profile in the Phase 2 study.  Six of the 27 patients reported mild treatment-related adverse events (AEs).  The most common AEs observed on study in more than two patients were falls (5/27, 18.5%) and rash (3/27, 11.1%).  Three patients in the FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">cohort experienced serious AEs, but none of these were attributed to treatment with AL001.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Among the symptomatic FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> cohort, AL001 treatment resulted in rapid and sustained 2-2.5-fold elevations of progranulin comparable to normal levels from an age-matched procured control group of healthy volunteers.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.825%;"></td>
    <td style="width:15.501%;"></td>
    <td style="width:16.673%;"></td>
    <td style="width:17.875%;"></td>
    <td style="width:13.406%;"></td>
    <td style="width:18.719%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="6" style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Table 1: Progranulin Levels from Baseline to 12 months with AL001 Treatment (ng/mL)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Plasma</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">CSF</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">AL001</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Age-matched procured control (N=46)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">AL001</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Age-matched procured control</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">(N=44)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Baseline (N=12)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">40.3 (2.64)</font></p></td>
    <td rowspan="3" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">64.6 &#x2013; 196.0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Baseline (N=10)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">2.3 (0.22)</font></p></td>
    <td rowspan="3" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">3.48 &#x2013; 7.06</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">25 weeks (N=9)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">99.0 (4.94)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">25 weeks (N=9)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">4.4 (0.43)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">49 weeks (N=7)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">86.8 (3.72)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">49 weeks (N=7)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">4.2 (0.54)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Arial;">CSF: cerebrospinal fluid, (): standard error of the mean.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Representative biomarkers associated with progranulin deficiencies measuring lysosomal function (CTSD and LAMP1) and complement activation (C1QB) were elevated in FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">patients at baseline compared to an age-matched procured control group, indicative of a disease state.  AL001 treatment resulted in a time-dependent and durable decreases over twelve months to levels seen in age-matched controls, suggesting that AL001 restores normal lysosome and complement function in these patients.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.422%;"></td>
    <td style="width:21.142%;"></td>
    <td style="width:21.152%;"></td>
    <td style="width:21.132%;"></td>
    <td style="width:21.152%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Table 2: CSF Lysosomal and Complement System Biomarkers of Disease Activity from Baseline to <br>12 months with AL001 Treatment (fmol/</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Symbol;">&#xf06d;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">L)</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Biomarker</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">AL001</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Baseline</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">(N=9)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">AL001</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">6 months</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">(N=8)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">AL001</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">12 months</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">(N=8)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Age-matched procured control (N=44)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">CTSD</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">5.2 (1.16)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">3.8 (0.57)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">3.1 (0.21)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">3.4 (0.08)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">LAMP1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">0.6 (0.12)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4 (0.06)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4 (0.043)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4 (0.01)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">C1QB</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">0.7 (0.12)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">0.6 (0.07)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5 (0.02)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5 (0.02)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Arial;">CTSD: cathepsin D, LAMP1: lysosomal-associated membrane protein 1, C1QB: complement C1q B chain, CSF: cerebrospinal fluid, <br>(): standard error of the mean.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Neuronal degeneration was assessed by measuring neurofilament light chain (NfL) in the plasma and CSF, and by measuring brain atrophy via volumetric magnetic resonance imaging (vMRI).  NfL showed within-patient variability in patients and over time, with mean levels stable at 49 weeks compared to baseline.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.478%;"></td>
    <td style="width:14.429%;"></td>
    <td style="width:16.862%;"></td>
    <td style="width:18.004%;"></td>
    <td style="width:15.223%;"></td>
    <td style="width:18.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="6" style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Table 3: NfL Levels from Baseline to 12 months with AL001 Treatment</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Plasma (pg/mL)</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">CSF (ng/mL)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Baseline</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">(N=12)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">25 weeks<br>(N=9)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">49 weeks</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">(N=7)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Baseline</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">(N=11)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">25 weeks<br>(N=9)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">49 weeks</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">(N=9)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">62.8 (13.57)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">67.5 (24.51)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">46.3 (12.93)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">7.3 (1.51)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">7.7 (1.63)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">6.5 (1.29)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Arial;font-style:italic;">Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 <br>for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Calibri;">Page </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Calibri;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Arial;">NfL: neurofilament light chain protein, CSF: cerebrospinal fluid, (): standard error of the mean.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Volume changes of the whole brain, the frontotemporal cortex and the ventricles were measured over one year and compared to a matched control cohort (N=7) developed from participants in the GENFI2 patient registry.  Treatment with AL001 resulted in a greater than 10% difference in the atrophy rates in favor of AL001 for the whole brain and frontotemporal cortex measures, and an approximately 50% reduction in ventricular enlargement.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:24.052%;"></td>
    <td style="width:22.344%;"></td>
    <td style="width:23.227%;"></td>
    <td style="width:30.377%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Table 4: Percent Volume Changes Observed in the Brain over 12 Months Using Volumetric MRI with AL001 Treatment vs. GENFI2 Matched Control</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">GENFI2 <br>control cohort</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">(N=7</font><font style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:bold;font-size:6.7pt;font-family:Arial;position:relative;">*</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">AL001</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">(N=8</font><font style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:bold;font-size:6.7pt;font-family:Arial;position:relative;">*</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Difference in relative <br>atrophy rates</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Whole brain</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">-4.6 (0.93)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">-4.1 (0.93)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">10.9%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Frontotemporal cortex</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">-1.8 (0.51)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">-1.5 (0.54)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">16.7%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Ventricles</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">25.6 (14.6)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">12.9 (4.99)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">49.6%</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Arial;">(): standard error of the mean. *N=8 for whole brain; N=7 for frontotemporal (FT) cortex and ventricles. <br>One GENFI2 control cohort patient with a 2.58% annual volume increase in the frontotemporal cortex is excluded as an image processing outlier.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">The potential clinical benefit of AL001 in FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> patients was measured using the CDR</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Arial;">&#174;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> plus NACC FTLD-SB scale, a standard FTD clinical rating instrument that assesses cognitive, functional, behavioral and language impairments over time, and which is also the primary endpoint of Alector&#x2019;s ongoing Phase 3 study of AL001 for the treatment of FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Treatment with AL001 showed a 47% slowing of clinical progression among the INFRONT-2 patients relative to matched GENFI2 controls.  The CDR</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Arial;">&#174;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> plus NACC FTLD-SB scores in the GENFI2 matched control group (N=10), showed an annual increase of 6.4 points from baseline over one year, indicating rapid disease progression.  In contrast, the annual increase in the AL001 cohort (N=12) was only 3.4 points over one year, a 3.0-point difference in annual change.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Conference Call Information</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Alector management will host a conference call to review and discuss data presented at AAIC 2021 today at 1:00 p.m. ET. Analysts and investors are invited to participate in the conference call by dialing (888) 705-0365 from the&#160;U.S.&#160;and&#160;Canada&#160;or (415) 817-9241 internationally and using the conference ID 5267479.  The live webcast can be accessed on the investor page of Alector&#x2019;s website at investors.alector.com where a copy of the AAIC 2021 presentations have been posted.  A replay of the webcast will be available on Alector&#x2019;s website approximately two hours after the completion of the event and will be archived for up to 30 days.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">About the Phase 3 INFRONT-3 Clinical Trial</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">The pivotal Phase 3 INFRONT-3 study is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of AL001 in treating symptomatic patients and at-risk people with FTD due to a progranulin gene mutation (FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">).  The study aims to enroll up to 180 FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;mutation carriers across approximately 50 sites in&#160;the United States,&#160;Europe&#160;and&#160;the Asia Pacific Region.  Participants will be randomized to receive AL001 or placebo intravenously every four weeks for the duration of the 96-week study and will be given the option to continue receiving treatment in an optional open-label extension study after the 96-week treatment period. &#160;The primary endpoint of the pivotal Phase 3 trial is the effect of AL001 on clinical decline by utilizing the CDR</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Arial;">&#174;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> plus NACC FTLD-SB scale, which evaluates clinical impairments in behavior, language, orientation, memory, judgment, and functional activities in trial participants. In addition, the trial will assess secondary clinical endpoints of clinical status, cognition and function, multiple biomarkers and safety.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">About Frontotemporal Dementia</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">FTD is a rare neurodegenerative disease but it is the most common form of dementia for people under the age of 60.&#160; It affects an estimated 50,000 to 60,000 people in&#160;the United States&#160;and roughly 110,000 in the&#160;European Union, with potentially higher prevalence in Asia and Latin America.  There are multiple heritable forms of frontotemporal dementia, and FTD-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GRN</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;patients represent 5% to 10% of all people with FTD.  Patients with FTD</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Arial;font-style:italic;">Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 <br>for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Calibri;">Page </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Calibri;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">frequently develop symptoms such as behavioral changes, lapses in judgement, and diminished language skills when they are in their 40&#x2019;s and 50&#x2019;s with the disease running its course in 7-10 years.  There are currently no FDA-approved treatment options available for any form of frontotemporal dementia.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">About&#160;Alector</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Alector&#160;is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases.  The company&#160;is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain&#x2019;s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies.&#160;Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.&#160; Alector&#x2019;s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer&#x2019;s disease. This scientific approach is also the basis for the company&#x2019;s immuno-oncology programs.&#160;Alector&#160;is headquartered in&#160;South&#160;San Francisco,&#160;California. For additional information, please visit&#160;</font><font><font style="font-weight:normal;font-size:10.0pt;font-family:Arial;">www.alector.com</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:11.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Arial;">(</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:5.36pt;font-family:Arial;">1) </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Arial;">The GENFI2 historic matched control group was selected on a blinded basis without access to clinical longitudinal data based on a propensity score matching technique combined with clinical adjudication of select baseline characteristics (NfL plasma levels, age, diagnosis and gender).</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Arial;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:11.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Cautionary Note Regarding Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the continued clinical development of AL001; the expected timing of reporting future data from the AL001 clinical trial; the potential benefits of AL001 or Alector&#x2019;s (the Company) other product candidates; and statements by the Company&#x2019;s chief medical officer. Words such as &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; &#x201c;intends,&#x201d; &#x201c;will,&#x201d; &#x201c;goal,&#x201d; &#x201c;potential&#x201d; and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Alector&#x2019;s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: the Company&#x2019;s plans relating to the development and manufacturing of its product candidates and research programs; the ability of the Company&#x2019;s clinical trials to demonstrate safety and efficacy of its product candidates, and other positive results; the timing and focus of the Company&#x2019;s future clinical trials, and the reporting of data from those trials; the Company&#x2019;s plans relating to commercializing its product candidates, if approved, including the geographic areas of focus and sales strategy; the expected potential benefits of strategic collaborations with third parties and the Company&#x2019;s ability to attract collaborators with development, regulatory and commercialization expertise; the Company&#x2019;s estimates of the number of patients in the United States who suffer from the diseases it is targeting and the number of patients that will enroll in its clinical trials; the size of the market opportunity for the Company&#x2019;s product candidates in each of the diseases it is targeting; the Company&#x2019;s ability to expand its product candidates into additional indications and patient populations; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy, and therapeutic effects of the Company&#x2019;s product candidates; the timing or likelihood of regulatory filings and approvals, including the Company&#x2019;s expectation to seek special designations, such as orphan drug designation, for its product candidates for various diseases; the Company&#x2019;s ability to obtain and maintain regulatory approval of its product candidates; the Company&#x2019;s plans relating to the further development and manufacturing of its product candidates, including additional indications that it may pursue; existing regulations and regulatory developments in the United States and other jurisdictions; the Company&#x2019;s continued reliance on third parties to conduct additional clinical trials of its product candidates, and for the manufacture of its product candidates for preclinical studies and clinical trials; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled &#x201c;Risk Factors&#x201d; in Alector&#x2019;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on May 5, 2021, and Alector&#x2019;s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and Alector assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Arial;font-style:italic;">Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 <br>for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Calibri;">Page </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Calibri;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Alector Contacts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Michelle Corral<br>VP, Communications and Investor Relations</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">650-808-7016</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font><font style="font-weight:normal;font-size:10.0pt;font-family:Arial;">michelle.corral@alector.com</font></font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">1AB (media)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Dan Budwick</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">973-271-6085</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font><font style="font-weight:normal;font-size:10.0pt;font-family:Arial;">dan@1abmedia.com</font></font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Argot Partners (investors)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Joseph Rayne<br>Argot Partners<br>212.600.1902<br></font><font><font style="font-weight:normal;font-size:10.0pt;font-family:Arial;">joseph@argotpartners.com</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img60799751_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img60799751_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &\!G<# 2(  A$! Q$!_\0
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M $I_V+CM_P!1?7J&WZ&#%JU_"?ENI#[.=W\ZT[;Q,X(%U"&']Z/@_E1-X8<
MF"X5O9UQ^HK(NK"YLSB>)E'9NH/XU+>9X'65[?>OU*2PM?16O]S.SM;VWO4W
M02!L=1T(^HJQ7GT4LD,@DC<HXZ$&NHTG6UNR(+C"S]F[/_\ 7KVLOSJ&(:IU
M?=E^#_R.'$8&5-<T-4;-%%%>Z< 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU2/4(>RS*/F3^H]J[,GS15XJC5?OK;S_ ."8XS"\CYX;?D7Z***]X\\****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZANXA)!('7VZCZU-7T\91FE*+NF>6TT[,****H04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW7]>1[%2$,52O'<[ZBH[>=+FW2:,Y5QD5)7V\9*24ELSPVFG9A1113$%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'C'?V=3Y,DT/5C< 6MPV90/D8_Q#T^M;E>>H[1NKH2&4Y!'8UVVFWHO[)9>
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M?$6YM)'8PV44<<:=AN0.3^);K[#TKSJMXTDU=G/.JT[(^E/^%[>$?^>6I_\
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M7XR>"+G ;59(&/:6VD'Z@$5\M44>RB'MI'V3IWBSP]JQ"V&MV$[GI&DZ[_\
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M\(_\\M3_ ._"_P#Q5?-=%'LHA[:1]*?\+V\(_P#/+4_^_"__ !5'_"]O"/\
MSRU/_OPO_P 57S711[*(>VD?2G_"]O"/_/+4_P#OPO\ \51_PO;PC_SRU/\
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M&E:QIVN6*WNF7D-U;MT>)LX/H1U!]CS64HN.YK&:EL7:***DH**** "BBB@
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M/_A&-?\ ^@'J?_@))_A1_P (QK__ $ ]3_\  23_  K[,HH]L^P>P7<^,_\
MA&-?_P"@'J?_ ("2?X4?\(QK_P#T ]3_ / 23_"OLRBCVS[![!=SXS_X1C7_
M /H!ZG_X"2?X4?\ ",:__P! /4__  $D_P *^S**/;/L'L%W/BB\TV_TXH+Z
MRN;4ODJ)XF3=CKC(YJK7M/[0O_'_ *#_ -<IOYI7BU;1=U<QG'E=A\,,MQ,D
M,$;RRN=J(BEF8^@ ZUI?\(QK_P#T ]3_ / 23_"KW@#_ )*#H'_7]%_Z$*^O
MJB<^5ETZ?,CXS_X1C7_^@'J?_@))_A1_PC&O_P#0#U/_ ,!)/\*^S**CVS[%
M^P7<^,_^$8U__H!ZG_X"2?X4?\(QK_\ T ]3_P# 23_"OLRBCVS[![!=SXS_
M .$8U_\ Z >I_P#@))_A1_PC&O\ _0#U/_P$D_PK[,HH]L^P>P7<^,_^$8U_
M_H!ZG_X"2?X5Z5\(_ASJK>(X->U>RFM+2SR\*3H4>63&!\IYP.N?4#&>:^@J
M*3JMJPXT4G<****R-@HHHH *\O\ B-\6K?PR\NDZ-Y=SJP&))#S';GW_ +S>
MW;OZ4GQ:^([>&;7^Q=)E U:X3,DJ];9#W_WCV]!SZ5\X,S.[.[%F8Y))R2:V
MIT[ZLQJ5+:(M:EJ=[J]_+?:C=2W-S*<M)(V2?;V'MT%5**LV-A>:G>1VEC;2
MW-Q(<+%$A9C^ K<YBM17LGAOX"7MRBS^(K\6:GG[-;8>3\6/R@_3=7IVD?"_
MP?HRKY6BP7$@ZR7?[XD^N&X'X 5FZL4:JE)GR>D;R,%C1G8]E&35Z/0=8F;;
M%I-\YQG"V[G^E?9=O:V]I'Y=M!%"G]V- H_(5-4^V\B_8>9\62Z+JL.[S=,O
M(]OWM\##'UXJDRE6*L"&!P0>U?<%5;S3;'48S'?65M=(1C;/$KC]11[;R#V'
MF?%%%?4^L?"'P=JZL5TXV,I_Y:6;E,?\!Y7]*\K\4? _7-)5[C1I1JML.3&%
MV3*/]WHWX'/M5JI%F<J4D>65J^'_ !)JWAC45O=)NW@D'WU'*2#T9>A%9LL4
MD$KQ2QM'(A*LCC!4CJ".QIE7N9['U1X ^)>G>-8!;R!;35D7,EL6X?U:,]Q[
M=1^M=S7Q):7=Q87<5W:3/#<0L'CD0X92.X-?4?PU\?1>--&V7!6/5K50+F,<
M;QVD4>A[CL?PKGJ4[:HZ:=3FT9W%%%%9&P4444 %%%% !5'6O^0#J/\ U[2?
M^@FKU4=:_P"0#J/_ %[2?^@FA SXLHHHKM. O6NB:M?0">STR]N(B<>9#;NZ
MY^H%3_\ ",:__P! /4__  $D_P *^AO@A_R3B'_KYE_F*]&K&55IVL;QHIJ]
MSXS_ .$8U_\ Z >I_P#@))_A1_PC&O\ _0#U/_P$D_PK[,HI>V?8?L%W/C/_
M (1C7_\ H!ZG_P" DG^%'_",:_\ ] /4_P#P$D_PK[,HH]L^P>P7<^,_^$8U
M_P#Z >I_^ DG^%12:%J\)(ETJ^0CDAK=QC]*^T:*/;/L'L%W/B!XWB;;(C(W
MHPP:;7V[-;PW,?ESPQRI_==0P_(USFI_#OPCJRD76@688_QP)Y+?FF*:K+JA
M.@^C/D6BO?->^ -A,KR:#J<MM)U$-T-Z$^FX8('X-7D/B3P9KWA.<)JUB\4;
M'"3I\T;_ $8<9]C@UI&:EL92A*.Y@UZ)X%^+.K>%7CL[]I-0TD8'E.V9(1_L
M,>W^R>/3%>=T4VD]&)-IW1]HZ+K6G^(-+BU'3+E)[:4<,O53W4CL1Z&M"ODG
MP)XYOO!.LB>(M+82D"ZML\.OJ/1AV/X5]6:;J-IJVG6^H6,RS6UP@>-U[@_R
M/MVKFG#E9U0GS(M4445!H%%%% '"ZDQ;4[HG_GJP_(XK<\+_ /'M<>F\?RKG
M[MS)>3N<9:1CQ]:Z7PUC^S7P,'S2"?7@5\9E/OYBY?XF>WC-,-;T-FBBBOLS
MQ KG_$=[/"\5O$Y167<Q4X)YKH*YSQ1'\UM)_O*?T_\ KUY><N<<'-P=MOS.
MK!).LDR/P_?SF]^S22,\;J<!CG!'/%=/7#Z5+Y6JVS?[87\^/ZUW%<^05I5,
M,XR=[/\  US""C5375!1117N' %<QXBLYS>"X5&>,J!D#.TCUKIZY34M:NS>
MR)!(8XXV*@ =<=S7CYW.BL/RU6]7I8[<"I^TO L>';&5)WN98RJ[=J;AC)/>
MNCK.T:^DO[(O*!YB-M)'?WK1KIRRE2IX6*I.Z>IEBIRE5?/N%%%%=YSA1110
M 4444 <#>?\ '[<?]=&_G71>&/\ CRF_ZZ?T%<[>?\?MQ_UT;^==%X8_X\IO
M^NG]!7Q>4?\ (P^\]O&?[O\ <;E%%%?:'B!1110 4444 0W47GVDT7]]"/TK
M@:]$KS^X79<RI_=<C]:^7XCA_#GZK\CU<LE\43K]"E\S2(<GE<K^O^%:-8OA
MELZ?(OI*?Y"MJO;RZ?/A*;\E^&APXF/+6DO,****[3 I:N0-)N<_W?ZUQ%=?
MXAE\O2F7/,CA?Z_TKD54LP4=2<"OC>()<V*C%=%^K/:RY6I-^9W=@"-.M@>H
MB7^0JQ3401QJ@Z* *=7U]./+!1[(\:3NVPHHHJQ' 7(VW4P]'(_6NC\,-FRF
M7TDS^@_PKG;S_C]N/^NC?SK?\+G]Q<#T8']*^)RAVS"WJ>YC-</?T-^BBBOM
MCPPHHHH **** "BBB@ HHHH **** "O"?V@=:WW6E:'&PQ&K74H![GY4_0/^
M=>[5\A_$#6_^$@\=:M?JX:$S&*$CH43Y5(^H&?QK6DKRN95G:-CFJL65C<:A
M.8+6(R2"-Y2H_NHI=C^2FJ]>Q? 305N]4U75IXPT4,(MD##(+/RWY*N/^!5O
M)V5SGC'F=CQVBM/Q'I+Z#XDU'2GS_HMP\:D_Q*#\I_$8/XUF4R3Z^\!:U_PD
M'@?2=09]TK0".4_]-$^5OS(S^-='7B_[/^M>98:KH<C\Q.MU$">S?*WX A?^
M^J]HKDFK2L=L'>*84445)04444 %%%% !1110 4444 %?.7Q^_Y'NQ_[!D?_
M *-EKZ-KYR^/W_(]V/\ V#(__1LM:4OB,JWPGE==Q\'_ /DJ>C?]M_\ T1)7
M#UW'P?\ ^2IZ-_VW_P#1$E=$OA9SP^)'U31117&=H4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'RM\8/^2IZS_VP_\ 1$=</7<?&#_DJ>L_]L/_
M $1'7#UV1^%'%/XF>J? '_D>[[_L&2?^C8J^C:^<O@#_ ,CW??\ 8,D_]&Q5
M]&USU?B.BC\(4445F:A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<K\0?%T?@WPM/?KM:\D/DVL9[R$=2/0#)/TQWKJJ^7_C#XH/B#QK+:PR;K
M+3<V\8!X+_\ +1OS&/HHJX1YF14ERHX*XGENKB6XGD:2:5R[NQR68G))J.BM
MSPAX9N?%OB2UTFV)42'=-+C/EQC[S?T'N0*ZMCC2NS:^'OPZO?&U\9'+VVDP
MMB:YQRQ_N)ZM[]!^0/TSHF@Z9X=TY+#2K2.W@7J%'+'U8]2?<U-I6EV>BZ7;
MZ;80B*UMT"(@_F?4D\D^IJY7+.;DSLA!104445!84444 %%%% !1110!RGC3
MX?Z/XTLR+J,07RKB&\C7YU] ?[R^Q_#%?,'B3PWJ7A769=,U.'9*G*./N2KV
M93W!_P#K'FOLJN/^(O@J#QGX<DA5574K<&2TE/'S=T)_NMT^N#VK2$[:,RJ4
M^;5;GR=5BQO;G3;Z"]LYFAN8'$D<B]585%+%)!,\4J,DB,596&"I'!!IE=)R
MGV!X*\40>+_"]KJL>U92/+N(Q_RSE'WA].A'L170U\X_ WQ(=,\5R:-,^+;4
MD^0$\"502/S&X?E7T=7+./*['93ES1N%%%%06%%%% !1110 4444 %%%% '@
M_P"T+_Q_Z#_URF_FE>+5[3^T+_Q_Z#_URF_FE>+5U4_A1QU?C9T?@#_DH.@?
M]?T7_H0KZ^KY!\ ?\E!T#_K^B_\ 0A7U]6=;=&U#9A1116)L%%%% !1110 4
M444 %%%% !6)XM\1V_A3PU=ZO< -Y2XBC)QYDAX5?Q/Y#)K;KYZ^._B8WVOV
M_A^"3]Q8*))@.AE8<?DI'_?1JH1YG8B<N6-SRW4=0NM6U*XU"]E,MS<2&21S
MW)_I56BK.GV%SJFHV]A:1F2XN)%BC0=V)P*ZSCW-CP?X/U+QGK L;!0D:8:>
MX<?)"OJ?4GL._P"9'T_X3\%Z/X.T\6^FP?O6'[ZYDYDE/N>P]AQ2^#/"EGX/
M\/0:;;!6EQON)@.99.Y^G8#TKH*YISYO0ZZ=-15WN%%%%9F@4444 %%%% !1
M110!Q?CKX;Z3XTMFE*K:ZJJ_NKM%Y/\ LN/XA^H[>A^8]<T/4/#FK3:9J<!A
MN8CT[,.S*>X/K7VA7#_$WP-%XQ\/LT"*-5M%+VK]W]8S['MZ''O6M.=M&95*
M=]5N?*U;'A?Q%=^%?$-KJUF3NB;#QYP)$/WE/U'Y'![5D,K(Q5@58'!!&"#2
M5T;G*G8^UM+U*VUG2K74;.3?;W,8D1O8]C[CH:MUXM\!/$QFM+WPW/)DP?Z3
M; _W"<.H^A(/_ C7M-<DH\KL=L)<RN%%%%24%%%% !5'6O\ D ZC_P!>TG_H
M)J]5'6O^0#J/_7M)_P"@FA SXLHHHKM. ^F_@A_R3B'_ *^9?YBO1J\Y^"'_
M "3B'_KYE_F*]&KDG\3.V'PH****DH**** "BBB@ HHHH *@O+.VU"TDM;R"
M.>WE&UXI%#*P]P:GHH ^=_B5\)'T&.76M 5Y=-'S36QRSVX]0>Z?J/<<CR:O
MN!E5U*L RD8((R"*^8OBSX$7PEKJWEC'MTF^):)0.(7[I].X]LCM713G?1G-
M5IVU1YY7K_P0\9M8:H?#-Y+_ *+=DO:EC]R7NOT8#\P/6O(*D@GEM;B*X@<I
M+$X=''56!R#^=:25U8SC+E=S[=HK%\):\GB;PKI^KI@-<1 R*.BR#AQ^# T5
MQO0[4[FU45R)&M9EB.)"C!?KCBI>E<U<>)I1<,((HS$#@%LY/O7'C<91PT/W
MKM<VH49U7[BV,$@J2"""."#73>&&)M)U["3/Z?\ UJP+QS/<-<["JRDL,^O<
M5T'AJ"2.UED=2JR,-N>^.]?*Y-%QQR4=5K]UM&>MC7?#Z[Z&Y1117VQX855U
M"Q34+8PN2I!RK#L:M45%2G&I!PFKIE1DXOF6YS=MIEKIUZCW=[%N0AE3ISV)
MKHP0P!!!!Z$5P=YYGVV?S3F3>=WYUT/ANZ\RU>W8_-&<KG^Z?_K_ ,Z^=RG'
M4HUWAHPY4[V[W7<]'%T)."JN5S<HHHKZ4\P*X34(VBU"X5P0?,)_ FN[J*6V
M@F(,L,<A'0NH.*\S,\O>-A&*E9HZL+B/82;:O<R_#<;)I[NPP'D)7W& *V:0
M    8 Z 4M=F%H+#T8TD[V,:M3VDW/N5-2O?L%DTP4,V0J@],FN=A\17J2[I
M-DB?W2N/R(KIKRT2]M7@DR W0CL:Y2\T2\M7PL;3(>C1KG\QVKQ,X>.A452@
MWRKMW\U_2.[!*A*+C/?S.HL;^'4(?,BR".&4]0:M5BZ!936<,TMP#'OQA6XP
M!GD_G6RK*PRI!'J#7KX&K4JT(RK*TF<=>$8U&H:H6BBBNLQ.!O/^/VX_ZZ-_
M.NB\,?\ 'E-_UT_H*YV\_P"/VX_ZZ-_.NB\,?\>4W_73^@KXO*/^1A]Y[>,_
MW?[C<HHHK[0\00D $DX ZDU@ZAXB6-C'9J'(ZR-T_ 56UW53-(UI W[I3AR/
MXCZ?2L6.-Y9%2-2SL<  <FOE\SSF?.Z.&?J_\OZ]#U<+@ER\]7[C>TO7+F6\
M2"Y(=9#@': 0>W2NDK"TK0FMIDN;EAO7E4'8^YK=KU<ICB8T/]I;O?2^]CDQ
M;I.I^Z"N%U*-HM2N59=N9&8?0G(KNJBEMX)R#+#'(1TWJ#BGF> >-IJ*=FF&
M%Q'L)-M7N97AJ-TL)&8$*[Y7/?BMJD "@!0 !P *6NK"T/J]&-*][&-6I[2;
MGW"BBD)"@DG ')-=!F<UXFN-UQ#;@\(NX_4__J_6L_2(//U2!<<*V\_AS4-[
M<&[O99ST9N/IV_2MKPQ;<37)'^PO\S_2OB*?^W9ES=+W^2_X8]V7[C"VZV_%
MG14445]N>$%%%(2 "3T% '!71W7DQ]9&/ZU8TF_-A>JY/[IOE<>WK^%4F.YB
MQ[G-)7YK"O*G5]K#=.Y].X*4.26QZ("",@Y!HK(\/WGVBR\EC\\/'U7M_A6O
M7Z'AJ\<12C5CU/G*M-TYN#Z!1116YF%%%% !1110 4444 %%%% '/^.-:_X1
M[P5JVI*VV6. K$?21OE4_F0?PKX^KWO]H#6O*TS2]$C;YIY&N90#_"HVJ#]2
MQ_[YKP2NFDK1N<M9WE8*^J?A)HG]B_#RPWIMFO,W<GOO^[_XX$KYGT'2I-<U
M^PTN+.ZZG2+(_A!/)_ 9/X5]FPPQV\$<,*!(HU"(HZ  8 J:STL516MSYV^/
M&B_8O%]MJJ)B/4( &..LB?*?_'2E>55],_&W1?[3\!/>(F9M/F6<$==A^5A]
M/F!_X#7S-5TW>)%56D=I\*=:_L3XAZ:[-B&Z8VDON'X7_P >VG\*^K:^((Y'
MBD62-BKJ0RL.H([U]F>'-737O#>G:JF/]*MTD8#^%B/F'X'(_"LZRZFE%Z-&
MG1116)N%%%% !1110 4444 %%%% !7SE\?O^1[L?^P9'_P"C9:^C:^<OC]_R
M/=C_ -@R/_T;+6E+XC*M\)Y77<?!_P#Y*GHW_;?_ -$25P]=Q\'_ /DJ>C?]
MM_\ T1)71+X6<\/B1]4T445QG:%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!\K?&#_DJ>L_]L/_ $1'7#UW'Q@_Y*GK/_;#_P!$1UP]=D?A1Q3^
M)GJGP!_Y'N^_[!DG_HV*OHVOG+X _P#(]WW_ &#)/_1L5?1M<]7XCHH_"%%%
M%9FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-XMUH>'O">IZK
MD;K>!C'GNYX0?]]$5\<,S.[.[%F8Y))R2:^BOCUJ1MO!MI8*V&O+L;AZH@)/
MZE:^=*Z*2TN<U9^]8*^B_@5X;73_  O-K<R#[1J+D1DCD1(2!^;;C^ KYWAB
M>>:.&-=TDC!5'J2<"OM'1].CTC1;+38<>7:P)"N.^T 9HJNRL%%7=R[1117.
M=(4444 %%%% !1110 4444 %%%% 'S1\;/#J:/XT%_ @6#4X_.('3S0</^?R
MM]6->:U]&_'G3!=>"[:_"_O+*Z&3Z(X(/Z[*^<JZJ;O$XZBM(M:9?RZ7JMIJ
M$!Q+;3),GU4@_P!*^T[>>.ZMHKB([HY4#H?4$9%?$5?7W@&Y-WX T&5B2WV*
M)"3U.U=O]*BLMF:4'NCHZ***P.@**** "BBB@ HHHH **** /!_VA?\ C_T'
M_KE-_-*\6KVG]H7_ (_]!_ZY3?S2O%JZJ?PHXZOQLZ/P!_R4'0/^OZ+_ -"%
M?7U?(/@#_DH.@?\ 7]%_Z$*^OJSK;HVH;,****Q-@HHHH **** "BBB@ HHH
MH BN;B*SM)KF9ML4*-([>B@9)_*OB_5]2FUC6+S4KC_6W4SS-[%CG'X=*^H_
MBKJ1TSX;:Q(C8>:,6Z^^]@K#_ODM7RA6]%:7.>N]4@KV/X">&Q<ZI>^(9TRE
MH/L]N2/^6C#+$>X7 _X'7CE?6'PLTD:/\.M)C*XDN(_M3GU,AW#_ ,=*C\*J
MJ[1)I*\CL:***YCJ"BBB@ HHHH **** "BBB@ HHHH ^8_C/X:70O&K7D";;
M74U-PN.@DSB0?GAO^!5YU7TG\=-(%]X%2_"@R:?<*^[N$?Y"/S*?E7S9753=
MXG'45I'2> M:.@>.-)O]VV(3B.4]O+?Y6_('/X5]>U\/5]E^%]2.L>%-)U%F
MW/<6D<CG_:*C=^N:SK+9FM![HUJ***Q-PHHHH *HZU_R =1_Z]I/_035ZJ.M
M?\@'4?\ KVD_]!-"!GQ91117:<!]-_!#_DG$/_7S+_,5Z-7G/P0_Y)Q#_P!?
M,O\ ,5Z-7)/XF=L/A04445)04444 %%%% !1110 4444 %<]XV\-Q^*O"5]I
M;*/.9-]NQ_AE7E3^?!]B:Z&BA.VHFKJQ\0.C1NR.I5E."".0:;78?%'25T?X
MBZM#&H6*607" =/G 8_J2/PKCZ[4[JYQ-6=CWS]G_6#-I6JZ,[?\>\JW$>?1
MQAA^!4?]]45QGP.OC:_$-;?=@7=K+%C/4C#_ /LAHKFJJTCJI.\3Z'UNZ^RZ
M9)@X>3Y%_'K^F:XRNL\0V<US;1M"I<QDDJ.N#6/I.F3SWT;21,L2-N8L, X[
M5\;G%*MB,:J:3MHE^K/<P<X4Z#DV/OY9].MK>QC9H_D\R0C@EB3_ "JWH&I3
MRW+6T\C2 J64L<D$>]-\418DMY@.H*G\.1_,UFZ/(8]6MR.[;?SXK.56IA<R
M5-2?*FE\M/Z]2E&-7#.5M7=_,[:BBBOLCQ0HHHH Y7Q':^5>+<*/EE'/^\/_
M *V*@T%W75H@F<,"&^F/_P!5=;/!%<Q&.9 Z'L:YZ;4K32KIX;*T3*_*[LQZ
M^@KYC&X&&&Q:Q<IJ,;I];WZV]3U*%>56BZ*C=V.EHJIIU^FH6WFJ-K X92>A
MJW7TE.I&K!3@[IGFRBXOEEN%%%%62%%%% !1110!SGB>642019(B*D^Q.:H:
M+?-:7RJS'RI#M8=L]C70:Y:BYTR0@?/%\Z_AU_2N-KXW-75PN/59/LU^5CVL
M)RU</R,]$HJO8S&XL()6^\R GZ]ZL5]A":G%26S/&DN5M,X&\_X_;C_KHW\Z
MZ+PQ_P >4W_73^@KG;S_ (_;C_KHW\ZZ+PQ_QY3?]=/Z"OC<H_Y&'WGM8S_=
M_N-RL_6;TV6GLRG$C_(GM[UH5ROB6<O?)"#Q&F?Q/_UL5]'FN)>'PLI1W>B^
M9YN$I>TJI/8Q:Z_1=,6SMQ-(O[^09.?X1Z5S^C6HNM3C5AE$^=OH/_KXKM:\
M;(,'&5\1-;:+]6=N85FK4U\PHHHKZH\D**** "BBB@ K+UZ[^S:<44X>;Y1]
M._\ GWK4KC=<N_M6HL%.4B^1?ZG\Z\K.,5[##.V\M%^OX'7@Z7M*JOLM3- )
M( &2:[NPMA9V,4/=1\WU[US&@VGVG45=A\D/SGZ]O\^U=A7G\/8:T95WUT7Z
M_P!>1T9C5NU304445]*>8%5[^3RM/N'](VQ]<58K*\0R^7I3+GF1@O\ 7^E<
MV,J>RP\Y]DS2C'FJ1CYG(5:NK-K:&VE_AFCW?C_^K%5@"Q  R3P*ZS6;,'10
MJC)MPI&/0<']*^(P>#]O1JSZQ5U_7HCW:U;V<X+NS"T6Z^RZG&2?DD^1OQZ?
MKBNTKSL'!R.M=]9S_:;.&;NZ GZ]Z]OAVO>,Z+Z:K]3AS*G9J:)J***^E/,"
MBBB@ HHHH **** "BBLSQ%JR:#X<U'59,8M8'D /=@/E'XG _&@#YF^*^M?V
MW\0]1=6S#:$6D?T3AO\ QXM7%4Z21YI7ED8L[L69CU)/4TVNU*RL<+=W<]3^
M!.B?;_&,^J.N8].@)4X_Y:/E1_X[OKZ.KS;X):+_ &9X#6\=<3:C,TQSUV#Y
M5'Z$_P# J])KEJ.\CJIJT2IJ=A%JNE7>GS_ZJZA>%^,X# C^M?&%[:2V%]<6
M<Z[9K>5HI%]&4X/ZBOMJOE[XRZ+_ &3\0KJ9$VPWZ+=)@<9/#?CN4G\:NB];
M$5EI<\_KZ+^ VM?;?"5UI3MF33Y\H/2.3+#_ ,>#_G7SI7HWP5UK^RO'T5J[
M[8=0B:W.>F[[RGZY&/\ @5:5%>)E3=I'TW1117*=@4444 %%%% !1110 444
M4 %?.7Q^_P"1[L?^P9'_ .C9:^C:^<OC]_R/=C_V#(__ $;+6E+XC*M\)Y77
M<?!__DJ>C?\ ;?\ ]$25P]=Q\'_^2IZ-_P!M_P#T1)71+X6<\/B1]4T445QG
M:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\K?&#_DJ>L_]L/\
MT1'7#UW'Q@_Y*GK/_;#_ -$1UP]=D?A1Q3^)GJGP!_Y'N^_[!DG_ *-BKZ-K
MYR^ /_(]WW_8,D_]&Q5]&USU?B.BC\(4445F:A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >!_M"79?6-%L\\16\DO_ 'TP'_LE>-5ZA\>9"_CZ
MW4@?)I\:C_ON0_UKR^NN'PHXZGQ,Z3X?V8O_ (@:% 1D?;$D(]0AWG_T&OKV
MOEKX-Q"3XGZ6Q_Y9K,P'_;)A_6OJ6L:VYM1^$****R-@HHHH **** "BBB@
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MS2O%JZJ?PHXZGQ,Z/P)?-IOC/3[M&VM'YF#NVXS&PZ_C165H_P#R%8?^!?\
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M+6D,@Z*Y!_$?_6KIQ]:=##3J4]T98>$9U5&6S+%AKL%[/Y)C:)S]W)R#6K7
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MZ^9?YBO1J\Y^"'_).(?^OF7^8KT:N2?Q,[8?"@HHHJ2@HHHH **** "BBB@
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MP4444 %%%% !1110 5\Y?'[_ )'NQ_[!D?\ Z-EKZ-KYR^/W_(]V/_8,C_\
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M7QUX+_Y'OP]_V$[;_P!&K7V+6=;=&E#9A1116)N%%%% !1110 4444 %%%%
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MH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RM\8/^2IZS_VP_\
M1$=</7<?&#_DJ>L_]L/_ $1'7#UV1^%'%/XF>J? '_D>[[_L&2?^C8J^C:^<
MO@#_ ,CW??\ 8,D_]&Q5]&USU?B.BC\(4445F:A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?-?QV_Y*#'_ ->,?_H3UYE7IOQV_P"2@Q_]>,?_
M *$]>95UP^%''4^)GHWP0_Y*/#_U[2_R%?3=?,GP0_Y*/#_U[2_R%?3=8U?B
M-Z/PA11161J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >#_M"_P#'_H/_ %RF_FE>+5[3^T+_ ,?^@_\ 7*;^:5XM
M753^%''5^-G1^ /^2@Z!_P!?T7_H0KZ^KY!\ ?\ )0= _P"OZ+_T(5]?5G6W
M1M0V84445B;!1110 4444 %%%% !1110!X?^T1_S+?\ V]?^TJ\.KW']HC_F
M6_\ MZ_]I5X=753^%')5^-FYX+_Y'OP]_P!A.V_]&K7V+7QUX+_Y'OP]_P!A
M.V_]&K7V+6=;=&E#9A1116)N%%%% !1110 4444 %%%% !1110 5\/5]PU\/
M5O1ZG/7Z!7T;\ ?^1$OO^PG)_P"BHJ^<J^C?@#_R(E]_V$Y/_14555^$FC\1
MZI1117,=04444 %4=:_Y .H_]>TG_H)J]5'6O^0#J/\ U[2?^@FA SXLHHHK
MM. ^F_@A_P DXA_Z^9?YBO1J\Y^"'_).(?\ KYE_F*]&KDG\3.V'PH****DH
M**** "BBB@ HHHH ***X/QA\5] \+))!#,NH:D,@6\#9"G_;;HOTY/M32;V$
MVEJSHO%'B?3O"6BRZGJ,F%7B.)3\\K]E4>O\NM?)OB3Q!>^*-=N=6OV!FF;A
M!]V-1T4>P'^-2^)_%6J^+M4-_JD^]AQ'$O"1+Z*.W\SWK%KIA#E.6I4YO0*Z
M?P#X5D\7>++73]K?95/FW3C^&('GGU/ 'UKG(();FXC@@C:261@B(HR68G
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M$OA9SP^)'U31117&=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&U#9A1116)L%%%% !1110 4444 %%%% 'A_[1'_,M_\ ;U_[2KPZO<?VB/\
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M_:%_X_\ 0?\ KE-_-*\6KVG]H7_C_P!!_P"N4W\TKQ:NJG\*..K\;.C\ ?\
M)0= _P"OZ+_T(5]?5\@^ /\ DH.@?]?T7_H0KZ^K.MNC:ALPHHHK$V"BBB@
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M"KT2J]A9Q:=IUM8VXQ#;Q+$@]%4 #^56*XY.[N=T596"BBBD,**** "BBB@
MHHHH *^3OBAHO]A_$+5($3;#/)]IB],/\QQ[!MP_"OK&O$OV@=%W0Z3KB+RI
M:TE..QRR?R?\ZTI.TC*JKQ/"Z](^"6M?V9X\6S=L0ZC"T)STWCYE/Z$?\"KS
M>K6F7\NE:K::A ?WMK,DR<]U(/\ 2NB2NK'-%V=S[7HJ"RNXK^PM[R [H;B)
M98SZJP!'Z&IZXSN"BBB@ HHHH *^<OC]_P CW8_]@R/_ -&RU]&U\Y?'[_D>
M['_L&1_^C9:TI?$95OA/*Z[CX/\ _)4]&_[;_P#HB2N'KN/@_P#\E3T;_MO_
M .B)*Z)?"SGA\2/JFBBBN,[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /E;XP?\E3UG_MA_P"B(ZX>NX^,'_)4]9_[8?\ HB.N'KLC\*.*?Q,]
M4^ /_(]WW_8,D_\ 1L5?1M?.7P!_Y'N^_P"P9)_Z-BKZ-KGJ_$=%'X0HHHK,
MU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^:_CM_R4&/\ Z\8_
M_0GKS*O3?CM_R4&/_KQC_P#0GKS*NN'PHXZGQ,]&^"'_ "4>'_KVE_D*^FZ^
M9/@A_P E'A_Z]I?Y"OINL:OQ&]'X0HHHK(U"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /!_VA?^/_ $'_ *Y3?S2O
M%J]I_:%_X_\ 0?\ KE-_-*\6KJI_"CCJ_&SH_ '_ "4'0/\ K^B_]"%?7U?(
M/@#_ )*#H'_7]%_Z$*^OJSK;HVH;,****Q-@HHHH **** "BBB@ HHHH \/_
M &B/^9;_ .WK_P!I5X=7N/[1'_,M_P#;U_[2KPZNJG\*.2K\;-SP7_R/?A[_
M +"=M_Z-6OL6OCKP7_R/?A[_ +"=M_Z-6OL6LZVZ-*&S"BBBL3<**** "BBB
M@ HHHH **** "BBB@ KX>K[AKX>K>CU.>OT"OHWX _\ (B7W_83D_P#145?.
M5?1OP!_Y$2^_["<G_HJ*JJ_"31^(]4HHHKF.H**** "J.M?\@'4?^O:3_P!!
M-7JHZU_R =1_Z]I/_030@9\64445VG ?3?P0_P"2<0_]?,O\Q7HU><_!#_DG
M$/\ U\R_S%>C5R3^)G;#X4%%%%24%%%% !1110!Y/\<O"8U/0(O$%M'FZT_Y
M9L#EH2?_ &4G/T+5\[5]NW%O%=VTMM<1K)#*ACD1NC*1@@_A7R#XS\-2^$_%
M-YI,A9HT;?!(1]^,\J?Z'W!KHI2TL<U:-G<P.E?5_P ,O%8\5^#[>:63=?VH
M$%T">2P'#?\  A@_7/I7RA7=_"?Q8/"_C");B39I]^!!<9Z*<_(_X'CZ,:JI
M&Z)IRY9'U-1117*=84444 %%%% !5/4['^T+)H0P5P=RD],U<HK.K3C5@Z<]
MF5"3A)26Z.7LO#]T+M&GVI&C G#9)QZ5U%<KJVK77V^2**5HHXSM 7@GWK3T
M+4GO87CG;=+'SGU%>)EM?!T:TL+13O?=];'=B:=:<%5G8UZ***]\\\S]9M'O
M-/:.,9=2&4>N*YFTTR[GND3R)$ 8;F92 !77W=U%96[33$A1V'4GT%4+/7[>
M[N%A*/&S<*6Z$^E>%F&$P=;$Q=6=I::=_P#([\/6K0I/DC=&M1117NG <GXD
MCV:DK]GC!_$<?X4SP]+Y>JJO_/12O]?Z5O:MIG]HQ)M8)*F=I/0Y[54TK0GM
M+H7%PZ%E^ZJ9//O7R]7+\0LR56$?=NG?\SU8XFF\-R2>MK&Y1117U!Y044V2
M1(D+R.J*.I8X%0_VA9?\_=O_ -_!_C42J0B[2:12C)[(L44R.:*7_5R(_P#N
ML#3ZI--70FK;A1113$%%%% ' WG_ !^W'_71OYUT7AC_ (\IO^NG]!7.WG_'
M[<?]=&_G71>&/^/*;_KI_05\7E'_ ",/O/;QG^[_ '&Y1117VAX@4444 %%!
M( R3@5 U[:(<-=0J?0R 5,IQC\3L-1;V1/15<7]FW2[@/_;05.K*XRK!AZ@Y
MI1J0G\+3!Q:W0M4M6E\G2KAL\E=H_'C^M7:Y[Q-=#;%:J>?OM_(?UKDS&NJ.
M%G/RLO5Z&V&I\]6*.<KNM-C\K3;=#P=@)_'FN+M(#=7<4(_C8 _3O7?  # Z
M"O$X<I.\ZOR_5_H=^93TC#YA7/>*6.VU7L2Q_E70US_BE<I:MZ%A_+_"O6SF
M_P!1G;R_-''@OX\?ZZ&-I:AM4M@?^>@/Y5W-<-I;;=4MC_TT _/BNYKAX=M[
M"?K^AOF7QKT"BBD8A5+,< #))KZ$\XYGQ-/NN88 ?N*6/U/_ .K]:H:/#Y^J
MP+V5MY_#FH;ZY-W>RSGHS<?3M^E;/ABV^::Y(X^XO\S_ $KXBF_KV9\RVO?Y
M+_ACW9?N,+;K;\6='1117VYX04444 %%%% !7R[\9-;_ +7^(5U"C[H;!%M4
M],CE_P#QXD?A7TMJVHQ:1H][J4_^JM8'F8>H4$X_2OC"[N9;V\GN[A]\T\C2
M2-ZLQR3^9K:BM;F%9Z6(:W?!VNVWAKQ19ZQ=6;7:VQ9EA5]N6*D YP>F<_A6
M%16[5SG3MJ>\?\-"VO\ T+DW_@4/_B:/^&A;7_H7)O\ P*'_ ,37@]%1[.)I
M[6?<]X_X:%M?^A<F_P# H?\ Q-'_  T+:_\ 0N3?^!0_^)KP>BCV<0]K/N>\
M?\-"VO\ T+DW_@4/_B:/^&A;7_H7)O\ P*'_ ,37@]%'LXA[6?<]X_X:%M?^
MA<F_\"A_\31_PT+:_P#0N3?^!0_^)KP>BCV<0]K/N>\?\-"VO_0N3?\ @4/_
M (FC_AH6U_Z%R;_P*'_Q->#T4>SB'M9]SWC_ (:%M?\ H7)O_ H?_$U@>,_C
M!8^+O"]UH[Z#+"TNUHYC<!O+96!!QM]B/QKR:BA4XK43J2>@44459!]/_!G6
MO[6^'UO [9FT^1K9L_W1\R_AM8#\*]"KYX^ FM?9/$][I$C82^@WH,_\M(^?
M_02WY5]#URU%:1V4W>(4445!84444 %?.7Q^_P"1[L?^P9'_ .C9:^C:^<OC
M]_R/=C_V#(__ $;+6E+XC*M\)Y77<?!__DJ>C?\ ;?\ ]$25P]=Q\'_^2IZ-
M_P!M_P#T1)71+X6<\/B1]4T445QG:%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!\K?&#_DJ>L_]L/\ T1'7#UW'Q@_Y*GK/_;#_ -$1UP]=D?A1
MQ3^)GJGP!_Y'N^_[!DG_ *-BKZ-KYR^ /_(]WW_8,D_]&Q5]&USU?B.BC\(4
M445F:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-?QV_Y*#'_U
MXQ_^A/7F5>F_';_DH,?_ %XQ_P#H3UYE77#X4<=3XF>C?!#_ )*/#_U[2_R%
M?3=?,7P2=4^)-LI/+V\H'UVY_H:^G:QJ_$;T?A"BBBLC4**** "BBB@ HHHH
M **** "BBB@ HHJ&XN[:T4-<W$4*G@&1PH/YT 345%!<V]TF^WGBF3INC<,/
MTJ6@ HHHH **** "BBB@ HHHH **** /!_VA?^/_ $'_ *Y3?S2O%J]I_:%_
MX_\ 0?\ KE-_-*\6KJI_"CCJ_&SH_ '_ "4'0/\ K^B_]"%?7U?(/@#_ )*#
MH'_7]%_Z$*^OJSK;HVH;,****Q-@HHHH **** "BBB@ HHHH \/_ &B/^9;_
M .WK_P!I5X=7N/[1'_,M_P#;U_[2KPZNJG\*.2K\;-SP7_R/?A[_ +"=M_Z-
M6OL6OCKP7_R/?A[_ +"=M_Z-6OL6LZVZ-*&S"BBBL3<**** "BBB@ HHHH *
M*** "BBB@ KX>K[AKX>K>CU.>OT"OHWX _\ (B7W_83D_P#145?.5?1OP!_Y
M$2^_["<G_HJ*JJ_"31^(]4HHHKF.H**** "J.M?\@'4?^O:3_P!!-7JHZU_R
M =1_Z]I/_030@9\64445VG ?3?P0_P"2<0_]?,O\Q7HU><_!#_DG$/\ U\R_
MS%>C5R3^)G;#X4%%%%24%%%% !1110 5Y7\;_"9U?PY'KEK'NN]-SYFT<M >
MO_?)Y^FZO5*9+%'/"\4J*\;J596&0P/!!IQ=G<4ES*Q\0T5T7CGPS)X2\6WF
MED-Y ;S+9C_%$W*_7'(/N#7.UV)WU.%JSL?5'PI\6#Q1X/A6:3=J%B!!<9ZG
M ^5_Q _,&NYKY2^&'BS_ (1/QA!-/)ML+H?9[GT )X;_ ("<'Z9]:^K>M<M2
M-F==.7-$****@T"BBB@ HHHH Y;Q'9^5=+<J/EE&&_WA_P#6K.TZ[-E>QS?P
MYPX]5/6NROK1+VT>!^,]#Z'L:YZ+PU<F<"62-8P>2IR2/:OE,PR[$0QBK8:-
M[N_HSU\/B:;H\E5[?D=2#D9'0T5%'/ [>5'-&S+_  JP)%2U]3&2DKIGDM-;
MF!XHEQ#;Q>K%ORX_K6'IR&34;91_ST4_K6AXD9CJ2J1A1&-OOR:9X=A\S4Q)
MCB)2V?<\?UKXS%7Q&:<OFE]VY[=+]WA+^3.NHHHK[4\,*XO6;B:;4IED8[48
MJJ]@*[2N/\0$G5Y,J!A5P?7CK_3\*\+B"_U9-/K_ )G?EUO:OT%M=>N;6S\D
M*)&!^5W.<#TJ]I6NSSWBP7(5@_"LHQ@U@0P2W$@CAC9V/8"NCTK0GMIUN;EE
MWKRJ+S@^YKR<MJX^M4@H-N*^ZWZ_F=F)AAX1ES)7?WE7Q.9/M4*G/E;,CTSG
MG^E85>@3017";)HU=?1AFJ_]DV&,?98_RKOQV25<17E5C-:]SGH8Z%.FH-;'
M$QR/%(KQL5=3D$=J[F2[2VLEGN3L^49'OCH*BCT>PBE$B6R[AR,DD?D35;Q!
M:S7-DAA4L8VR5'4C%7A,'B,NH59W4GT2O]Y-:M3Q-2,=D36FMV=W+Y:LR.>@
MD&,_2M&O.Z['0;B6XTT&8EBCE0QZD<?XU659M/%3]E56N]T+%X.-*//!Z&G1
M117OGGG WG_'[<?]=&_G71>&/^/*;_KI_05SMY_Q^W'_ %T;^==%X8_X\IO^
MNG]!7Q>4?\C#[SV\9_N_W&Y1117VAXA%/<16T1EF<(@[FN>O/$DKDK:((U_O
ML,M^7050UFXEGU*99"=L;%57L!_]>J]K9SWDFR",L>Y[#ZFOD<=F^(K570P]
MUK;3=_Y'L8?!TX1YZFOY#9KF>X.9I7<_[1S45=+;>&8P ;F9F/\ =3@?G6@F
MBZ>@P+93_O$FL:>1XRK[U1I>KU_4N6/HPTCKZ'%4Z.22)MT;LC>JG!KM&T?3
MV&#:I^&152?PW:2 F%WB/UW#_/XTYY!BX>]!I^C".849:--&3:^(+R @2$3)
MZ/U_.J%W<O=W4D[]7/3T'85;O=%N[,%ROF1C^).<?45G5Y^*J8N*5'$-Z=&=
M%*-%OGIV^1T'AJSR[W;#@?(GU[FNDKF]$UA(U2SG"JHX1QP/H?\ &NDKZ[)G
M1^JQ5)W[^IX^-4_:MS^7H%8WB2/?IRN.J2#\B"/\*V:J:G#]HTRXCQD[,CZC
MG^E=6.I>UPTX+JF94)<M6+\SB8I#%,D@ZHP;\J] !# $'(/(KSRNWTF?[1I<
M#YR0NT_4<5\_PY5M.=+O9_=_PYZ.90]V,B[6/X@OOL]G]G0_O)N#[+W_ ,/S
MK4GFCMX'FE;"(,DUP][=O>W3SOWZ#T'85Z.=8U4*/LXOWI?EU.; T/:3YGLB
M  LP4#))P *[JPM19V44'=1\Q]3WKGO#UAY]R;IQ^[B/RY[M_P#6_P *ZJN;
M(,&X0>(EN]%Z?\']#3,*UY*FN@4445]&>:%%%% !1110!YG\<=;_ +-\#"P1
ML2ZC,L>,\[%^9C^84?\  J^:J]/^.>M_VAXVCTZ-P8M.@"$#_GH_S-^FP?A7
MF%=5-6B<E5WD'6N^7X,^-V4-_9D0R,X-S'G^=9/PZT7^WO'NDV;+NA6832\<
M;$^8@^QP!^-?7-34FXNR'3IJ2NSY=_X4QXW_ .@;#_X%1_XT?\*8\;_] V'_
M ,"H_P#&OJ*BH]K(U]C$^7?^%,>-_P#H&P_^!4?^-'_"F/&__0-A_P# J/\
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M_P"2IZ-_VW_]$25P]=Q\'_\ DJ>C?]M__1$E=$OA9SP^)'U31117&=H4444
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MMCJ"_=NK>.8?\"4'^M36Z&E![HN4445@;A1110 4444 %%%% !1110 4444
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MY?'[_D>['_L&1_\ HV6OHVOG+X_?\CW8_P#8,C_]&RUI2^(RK?">5UW'P?\
M^2IZ-_VW_P#1$E</7<?!_P#Y*GHW_;?_ -$25T2^%G/#XD?5-%%%<9VA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?*WQ@_Y*GK/_;#_P!$1UP]
M=Q\8/^2IZS_VP_\ 1$=</79'X4<4_B9ZI\ ?^1[OO^P9)_Z-BKZ-KYR^ /\
MR/=]_P!@R3_T;%7T;7/5^(Z*/PA11169J%%%% !1110 4444 %%%% !1110
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M1F\0^*M,TI02+F=5?'9!RY_!037V0 %    '  K.L]D:4%NQ:***P.@****
M"BBB@ HHHH **** /!_VA?\ C_T'_KE-_-*\6KVG]H7_ (_]!_ZY3?S2O%JZ
MJ?PHXZOQLZ/P!_R4'0/^OZ+_ -"%?7U?(/@#_DH.@?\ 7]%_Z$*^OJSK;HVH
M;,****Q-@HHHH **** "BBB@ HHHH YCXB:8=7^'VM6BKN?[,94'<LA#@?\
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MJSUL:T5HV%%%%8FX4444 %4=:_Y .H_]>TG_ *":O51UK_D ZC_U[2?^@FA
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M[C532]-M=&TNVTZRC$=M;1B.-?8=SZD]2?6K=<DI<SN=L(\JL%%%%24%%%%
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MBB@ HHHH **** /._C#X2'B+PB]];Q[K_3 TT>!R\?\ &OY#(]U]Z^8J^X2
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M ,-!Z5_T [S_ +^K1_PT'I7_ $ [S_OZM> 44>RB'M9'O_\ PT'I7_0#O/\
MOZM'_#0>E?\ 0#O/^_JUX!11[*(>UD>__P##0>E?] .\_P"_JT?\-!Z5_P!
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M 44>RB'M9'O_ /PT'I7_ $ [S_OZM'_#0>E?] .\_P"_JUX!11[*(>UD>_\
M_#0>E?\ 0#O/^_JT?\-!Z5_T [S_ +^K7@%%'LHA[61]2>$?BSH'BS4%TY$G
MLKY_]7'< 8DXSA6!Z^QQ[5WM?$EK=365Y#=V[F.>"19(W'56!R#^=?:\$GG6
M\<N,;T#8],BL:D%'8VI3<MR2BBBLS4**** //_B;\.8O&5@+RR"1ZS;KB)C@
M"9?[C'^1[9]Z^9+NTN+"[EM+N%X;B%BDD;C#*1V(K[;KC/'7PWTKQK!YK_Z+
MJ:+B.[1<D^BN/XA^H[5K"I;1F-2GS:H^4:56*L&4D,#D$=JWO%'@S6_"-WY.
MJVC+&3B.XC^:*3Z-Z^QP?:L"NA.YS-6W.]\/?%_Q7H*+#)=)J-LO CO 78#V
M<$-^9(]J]&TOX_Z-.%75-*O+1SU:!EE7Z\[3^AKY\HJ73BRU4DCZJM/BYX(N
MP,:T(F/\,T$BX_';C]:TD^(7A"1 P\1Z< ?[TX!_(U\AT5'L47[9GUXWQ!\(
M(I8^(]-P/2<$_D*S[OXM>"+13G6TE8=%AAD?/XA<?K7RG11[%![9GT'JWQ_T
M:!672M*N[M^@:=A$GUXW$_D*\O\ %'Q0\3>*5>">[%I9-P;:TRBL/1CG+?0G
M'M7&45:A%$2J28445Z)X,^$.N>)6CNKY'TW33AO,E7]Y(/\ 80_S.!]:;:6Y
M*BWHCD?#OAO4_%.JQZ=I=N996Y=CPD:]V8]A_D9-?4_@KP98>"M%%E:?O)Y,
M-<W+##2O_11V';ZDFKGASPQI/A7318Z3;"*/J[GEY3ZLW<_R[8K8KGG4YM#J
MIT^75[A11169H%%%% !1110 4444 %%%% !1110!X/\ M"_\?^@_]<IOYI7B
MU>U?M"@_;M ../+FY_%*\5KJI_"CCJ_&SH_ '_)0= _Z_HO_ $(5]?5\@^ /
M^2@Z!_U_1?\ H0KZ^K.MNC:ALPHHHK$V"BBB@ HHHH **** "BBB@ HHHH Y
M'X@>!;7QOHODDI#J,&6M;@C[I[JW^R?TX/L?EC5=*O=%U*?3M1MW@NH&VNC?
MS'J#U![U]JUR_C/P)I/C6P$5ZIBNXP1!=QCYX_8_WE]C^&.M:0J<NC,JE/FU
M6Y\C45U'B[P#KO@ZX/V^W,EF6Q'>0@F-O3)_A/L?PS7+UTII[',TUHSL/#7Q
M.\4>&%2&VOOM-HG MKL&1 /0'.5'L"!7IND?M :;*JKJ^D7-N_0O;.)%)]<'
M!'ZUX%14N$64JDEL?55G\7?!%X!_Q.1"Q_AF@D7'X[<?K6DGQ"\(.H8>(].P
M?6< _D:^0Z*CV*+]LSZ[D^(?@^)=S>(]/(SCY9@W\JR+WXR>";13LU.2Z;^[
M!;N?U8 ?K7RW11[%![:1[GK'[0485DT31'+=I;U\ ?\  %Z_]]5Y=XC\<^(O
M%3$:IJ,CP9R+>/Y(A_P$=?J<FN=HJU"*V,Y3E+<***[WP5\*M;\6/'<SHVGZ
M6<$W$J_-(/\ IFO?Z]/KTIMI;B2;T1SGA;PMJ7B[68]-TV/+'YI96^Y$G=F/
M^<U]6>%/"UAX0T*+2[ $A?FEE8?-*YZL?Y>P %/\-^&-+\*:6NGZ5;B./J[G
MEY6_O,>Y_P BMBN><^8ZJ=/E]0HHHK,T"BBB@ HHHH *HZU_R =1_P"O:3_T
M$U>JCK7_ " =1_Z]I/\ T$T(&?%E%%%=IP'TW\$/^2<0_P#7S+_,5Z-7G/P1
M!'PXAR.MS+C\Z]&KDG\3.V'PH****DH**** "BBB@ HHHH **** "N ^+WA3
M_A)/!TEQ!'NOM.S<18'++CYU_$#/U45W]'6FG9W$U=6/AZBNX^*7@X^$O%<A
MMX]NFWI,UL0.%Y^9/^ D_D17#UV)W5SB:L[,^B_@?XM_M7P_)H-R^;K3AF(D
M\O"3Q_WR>/H5HKQ3P3K-YH/BJUOK$GS55U*]F!4\$=_7\**PG3=]#>%1<MF?
M8-%%%8FX4444 %%%% '%ZU;?9M3E &%?YU_'_P"OFK7ANX,=\\/\,BY_$?Y-
M;FHZ9#J*+O)1U^ZPJI;6EAHCEYKD&5A@%NH'L*^8_LVKA\=[=-*%[WOWW7Z'
MJ?68U*'LWK*QLT4R.5)HP\;JZ'H5.13Z^F335T>6U8*PM2U]K6Z:"")6*<,S
MYZ^@K=KD-?LVM[\R@?NYOF!]^X_SZUY6<UJ]'#\]%VUU]#LP4*<ZEIG0Z7J*
MZC;E]NR1#AES^M7JX_P_)(FJHJ?=<$./;&?YUV%:95BY8K#J<]UH_,C%T52J
M6CL%%%%>D<P4444 126MO,X>2")V'=D!-2*JH,*H ] *6BI4(IW2U'=M6"BB
MBJ$<#>?\?MQ_UT;^==%X8_X\IO\ KI_05SMY_P ?MQ_UT;^==%X8_P"/*;_K
MI_05\7E'_(P^\]O&?[O]QN4445]H>(12VMO/_K8(W/JR@U7_ +)L/^?6/\JN
MT5E*A2F[RBG\D6JDULR&*TMX#F*"-#ZJH!J:BBKC&,5:*L2VWJPHHHJA!7.W
M7B1H[ADMXD:-3C<Q/S?2K6N:F+6 V\3?OW&#C^$?XUR=?-9QFDZ4U1H2LUN_
MT_S/3P6$4H\]1>AW=A>)?6BSH-N>"OH:LU1TFT-GIT<;_?/S,/0GM5ZO>PSJ
M2HQ=7XK*YY]514VH[!5;4+H6=C+-W ^7Z]JLUS'B2\\R9+1#Q'\S_7M^G\ZP
MS'%?5L/*?79>O]:FF&I>UJ*/0PB<G)ZUV.@VWV?3$8CYI3O/T[?I7+V%J;R]
MB@'1C\Q]!WKN@ J@ 8 X KPN'L-><J[Z:+]?Z\ST,QJV2IH6BBBOJSR HHHH
M **** "BBB@#B?B3X!7QSI,"P3I;ZA:,S02.#M8'&Y6QT!P.><8]Z\!O_ACX
MRT^X,,F@W4N#P]N!*I]\KG]:^M**N-1QT,Y4U)W/"_A=\*M5L=>@UW7[<6L=
MKEX+=F!=WZ!F Z <GUR!VKW2BBE*3D[LJ,5%604445)04444 %%%% !1110
M4444 %%%% !1110 4444 97B30X?$GAR^T>=MJ7414-UVL.5;\" ?PKYCU+X
M7^,=,O&MSHEQ<@'Y9;4>8C#U!'3\<&OK&BKC-Q(G34CYU\&_!36-0OHKGQ%%
M]AT]#N:'>#++[8&=H]2>?;O7T1'&D4:QQJ%1 %51T ':G44I2<MQQ@H[!111
M4E!7F_Q5^',_C*"WO],>-=3M4*;)#@3)G.W/8@YQVY.:](HIIM.Z%))JS/D6
M;X=>,8)6B?P[J!93@E(MX_ C(-1_\(!XN_Z%O4__  ';_"OKZBM?;,R]@NY\
M@_\ " >+O^A;U/\ \!V_PH_X0#Q=_P!"WJ?_ (#M_A7U]11[9A[!=SY!_P"$
M \7?]"WJ?_@.W^%'_" >+O\ H6]3_P# =O\ "OKZBCVS#V"[GR#_ ,(!XN_Z
M%O4__ =O\*/^$ \7?]"WJ?\ X#M_A7U]11[9A[!=SY!_X0#Q=_T+>I_^ [?X
M4?\ " >+O^A;U/\ \!V_PKZ^HH]LP]@NY\@_\(!XN_Z%O4__  ';_"C_ (0#
MQ=_T+>I_^ [?X5]?44>V8>P7<^0?^$ \7?\ 0MZG_P" [?X4?\(!XN_Z%O4_
M_ =O\*^OJ*/;,/8+N?(/_" >+O\ H6]3_P# =O\ "I(/AUXQN)EB3P[?JS'
M,D6Q1]2< 5]=44>V8>P7<Y;X>^%#X.\(P:;*RM=.QGN64Y4R-C@>P 4?A74T
M45DW=W-4K*R"BBBD,\E^*_POO?$UZNN:)L>]$8CGMG8+YH'0J3QG'&#CH/Q\
M=?X?>+T<J?#FHDCT@)'YBOKRBM(U&E8RE23=SY!_X0#Q=_T+>I_^ [?X4?\
M" >+O^A;U/\ \!V_PKZ^HJO;,7L%W/D'_A /%W_0MZG_ . [?X4?\(!XN_Z%
MO4__  ';_"OKZBCVS#V"[GR#_P (!XN_Z%O4_P#P';_"C_A /%W_ $+>I_\
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M"Y66UL1<7:\BYNR)'!]1V7Z@ UU]%%9MM[FB26P4444AA1110 4444 %%%%
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M6/Q*I4=4M%Y^?]=#W,-26'I.<]^IN>';+R;=KIQAY>%]E_\ KUMTBJ%4*H
M& !VI:^NPF'CAJ,:4>AX]:HZLW-A111709A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD2DV[(E)"J68@ <DGM7*ZSK'VLFW@)$ /)_OG_"HM4UF6_)CCS'!_=[M]?\
M"LZ**2>58HE+.QP *^3S3-W7_<8?9]>_DO+\SU\+@_9_O*F_Y"P0R7$RQ1*6
M=C@"NUTZQ2PM1$O+'EV]34&DZ4FGQ;GPT[#YF]/85I5Z>499]6C[6I\;_!?Y
MG+C,5[5\D=E^(4445[9PA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7-:WYF19V,]]+LA3..K'HOUKK=.TN'3X_E^>4_><_P!/05;BAC@C$<2*B#H
M*?7TV7Y32POOR]Z??MZ?YGF8C&2JZ+1!1117K'&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU:-%%?0T:%.C'DIJR/.G4E-\TG=A1116I 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>alec-20210729_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-07-29T13:35:13.5392+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>alec-20210729_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-07-29T13:35:13.5632+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="alec-20210729.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>alec-20210729.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-07-29T13:35:13.4550+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://alector.com/20210729" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:alec="http://alector.com/20210729" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alec-20210729_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alec-20210729_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>alec-20210729_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="alec-20210729.xsd" xlink:type="simple"/>
    <context id="C_017fb68c-2b73-4d25-8a36-08187e8cbe57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <startDate>2021-07-29</startDate>
            <endDate>2021-07-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_49c01743-ec62-4852-9541-dd9e5294637e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_7172732d-d8d2-4293-8b7c-cd997a97f281">0001653087</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_57e34499-e102-4ab6-a3e1-f421cb33cf0d">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_1c21b7b8-bb41-4106-af63-7742a446f0c3">2021-07-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_b331cc29-0652-47a5-9cba-fb915a041955">Alector, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_cb97b522-68ed-4353-a64a-57c3853df4a9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_1dad3607-97c5-4132-a8ce-209c5eb90d48">001-38792</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_31dc34bb-dd31-4179-b9a0-adc4da5dc08b">82-2933343</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_36e832b3-e2b4-4ae0-9318-071f207ad13a">131 Oyster Point Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_feea7dd1-f54e-4ba2-b3d9-e3bfde97c952">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_4975b273-9684-4f29-afd4-9fa6ebad82d1">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_a7f68c3e-37b2-4136-a2ec-7ab7b11e5f93">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_75e49c21-208f-4ce3-958b-b663d66645c1">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_d1be4cb6-a72a-4aac-8465-50cb3ae60cc4">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_782b6cb3-d2ad-4bad-b0b3-0f70b77c22c7">231-5660</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_e6e704d6-ab11-48f7-bc81-f24709c46776">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_c949abb3-d66d-4979-af53-14a484194d63">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_dedc8c92-47a8-4289-a1d6-1eb87579d2da">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_2a076777-2535-4add-9779-b9008b12a105">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_3bc0796a-5dc1-4ff3-9a54-602d6e71a66e">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_f89ca3b6-930f-4629-bf6e-9175184be3cd">ALEC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_43b02bf9-f009-4af9-ba1a-4af9733f639a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_017fb68c-2b73-4d25-8a36-08187e8cbe57"
      id="F_1c978d3e-5280-4a60-ab27-5fb5546c0818">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140277639120504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 29,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alector, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001653087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2933343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">131 Oyster Point Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">231-5660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALEC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3]D.*.[=,\6;(:2'PQ=V6+W" A)L\F6YK)Z_&KU:LK,5.N[9_R-[U#H#LEI
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M$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( "* _5*7BKL<P
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M[L#TA(XA+@W#<Z1#BV'7T8B+[,)&G\-8AQ#G\3\Q4EUC!4NJ#AX"#SE&<)W
MD!ILDU;!>"CTN*+N@U6/@24DM0H#E>QV3N7TR@ZN6>1>9!CG*(.XLH/P4:V%
M&@/8-SF0!)?DJG547>EYIM<WDUM)Z.#<@V#OX96,'<V/'W?W U!+ P04
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MUDX:?^:+X3]>?P%02P$"% ,4    "  B@/U2!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "* _5+<
MQSPQ[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( "* _5*97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ (H#]4NL&C[1$!
MV!   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( "* _5*?H!OPL0(  .(,   -              "  8<,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ (H#]4I>*NQS     $P(   L
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64$L%!@     )  D /@(  .@3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="alec-20210729.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="alec-20210729.htm">alec-20210729.htm</File>
    <File>alec-20210729.xsd</File>
    <File>alec-20210729_lab.xml</File>
    <File>alec-20210729_pre.xml</File>
    <File>alec-20210729ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "alec-20210729.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "alec-20210729.htm"
     ]
    },
    "labelLink": {
     "local": [
      "alec-20210729_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alec-20210729_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "alec-20210729.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "alec",
   "nsuri": "http://alector.com/20210729",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alec-20210729.htm",
      "contextRef": "C_017fb68c-2b73-4d25-8a36-08187e8cbe57",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alec-20210729.htm",
      "contextRef": "C_017fb68c-2b73-4d25-8a36-08187e8cbe57",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://alector.com/20210729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-21-000607-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-21-000607-xbrl.zip
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MR\2FYGLZ$Y;F^\:JAJ)TYR70MF0:[AO$/%BC"[]C&+,=ZEF ',PIXS) "])
M@T<ML#7/MGU*?7M5C'U*0)3<2/K?6EX9U0DV+>LM-GVM#'=;&?[06F_[<?--
ML,.'L9XO05B+%%VI[5DI*A]+[_(0A8'<DA7?"8ZZ,B")/K$L+_<C;VZ3ECY_
MK,\;I<OWN4MK 7Q6/(1AT?PVH^7;?>%_4><LL.$P389I*!-IO62,/!$E#Y+>
MY$=)ALC!OZ( !"J8D&&&0GE0'0<ZS!.4A8-1E+-8)*,LFJ",Y6$63%3-LD+B
MP<2*_,'R7(?T:>,AR%&@<19/JF\!R.OD0=:3D?50)HEF[V&LEF0Q==+>-&%@
M:C0DXBMQK_BK?/?B$1UO4+XS/$'$X.C9BPT$8H4E;,W@8%][A&##"6SL^0[!
M 35LS?4-R[:M5:VU?Z=A#L0D,X)'<9EFFCU?:O&2)/(84$8.]+DJ][NV81R]
M9*MMB^!*   8IR& AE,GI-R.P&@RJ%DRR]S)*/) E'UBH_;E+:*ZUH""3]J@
M.MUN-3*V/C09^Z[A,D\Z'98%3H=KRR5@4\?$8(9C$!<H?.6%PR[H,1_P$=]]
M!B$*DC3ZD6CX:?9H4$[_.0$#N#&A4S0\<Z3/(P6#PB]*UD0\$^L0W'=\5YW9
MX&"#.D#$!$0S$9YCF[;+*5\YJ^TF%5(.R\-&U1EK4L>GUT$ /O0/1,P !>Q/
M@>%%R4P,CNF^=[ <:1=E:^*>)F[*-!N,"1M34S>Q 5/%KJTV(&J:XQ'*B+;R
MJ21SQ-W)LI%(:Q)?DL1U@0UY:OLR)%Z6?4[B[W/,G;L1AWXYO?ADI14NCTC!
M:1HN.OQ."9#2!0*(MCY X$Q_^>2+ET_8(.8:&C'F&]FU0_9F@Q]D."X"'Q\O
MX+<)+BEV&O;D,?G%@7I^'_D1R[+W7,Z?#U=IA,R&JZAI'E;_R<\'NX2\#Y__
M5C/-"^CII4Q"MCRM?#* -O;?-\6HYIB:8W:98PI6N2K/OE-:1E0V+%A@#_T0
MWCR9:2OO[JASSC:TO\_S-=NU&#:Y3[ 1!#IVF6E@2Z/<$C9AEB56#N<5AON$
M4$_9)=M9CP$G# BQFR?^ESJ]_[L7UC\D\P:.ZS/=L["K:P$V+.IB+[ $=HEM
M$L?PA.ZO?$=$:1H51M%6./?LTT6[YMB:8[]'CC5T3Z->X.) TUQL,/CE,<+4
M+UO7 TMW5UYXJ-1M%5-4)T8_B\=*:^U-.^W>QM2]OD!79]WSL_\M5#+ZS-(O
M(D>?/KV&U]>7V%1>K+%AIMP,+#LQE\%E@;P)\E7:"0SM"]C<0IW9-I<3$F8(
M!B0 J'=R21'8^2'ORQCU4.:)L QQ$0 4U$'5Q=JX9BZX,N3IIA =[4OI81^I
M)&D:'*EU\JH2= =D-Y1'7<NTJR+@33U,E[R&Y%GC,@C^5'^J^<;[Y;'LR(4[
MVR.YBZ^0SU*IS5\[B]5W;8?K IO4T4 "6AIF'K6Q&7BF:5B^E&_KV9E8C?X7
M-?AV,?9=6*+Z0:FI$WQ#)!V"(%HHW\)GZ6Y]D%Y"7E0 TBM.U!+0*!.J%$RK
M3*J3%]Z&:EFHN-!2HEWU%4UDYP\A="U).88!PI=4W(<9U L>[U!FOB\/E9:%
MY:6WG*4\*]+I^-?6G_1]]KC^-"WD&NO8"S!/6^L^%_\M-VG.QLI>ONES%[-/
M/X29+J?7?PR7#=F=*(QMS +0B2T6/;!)=E1<=?QFV\A9$1+..D3+6Z*2G5P,
M$/1.RN-K+^0M4EGCXY#'9N3M=8QFKGHZ1#/7NX")F(U E#&0:G+G=0HRE8$<
M97$,@D^NBB/.<H:"-!F@,,_035]^IB!;I7P$.7?V20.8#QE8=0#O0J9>]L[1
M_M4)H0>(Y4H2JDOJSZ+_ OA ]#]ML3O+L@0DK1*='>EYQ>HW--U.XO*^9M07
M$9>1Y6(B5C$1:!:\T[N^>JMKQ<L&.@/Y/BQSH*'OV5E)>SC/&2@6+JW?BW$_
M],(<N6Z#P(QYD9%='7 ,98".!)C&H(L>+X]>#T&MRF7O2%#2FPOCQVOD43!*
MXS#K%TZ$,M*?.%'"5#VY\FD_?-P].0WY Y3UP?)26MP3X)* <: 2XN&A(!3_
M* @CP8L'?J2TN"0JT+_#)!/JO(!'_>LLZ6P<2@I@@\)2V)<5JLZF2U=]'AQ*
M R&1DN4!; 24C;S_0(]RF+)J%#*5[!$6@\E&?A]EQ8@.86)I.47U?AIXA8Q_
MFO4,]4V3G02NM%3*G0!?S5\NW;3IR:F1/[-&UG.#[ZITO)9-&V_6%HHJ+Q^-
M/75,T4!),4FX)8U^3RKD+9#B!X^0^%8JU?3V*#;*DZ/UY5;-)$ZJME?;ID@:
MMD%>2(1R'+!CW9U.A:HJ/VZE5]5W*)2ZQ1!%J4ZNDL9[AK5KC#QBY%QD?AH.
MU=T1'V#]O\;<TYE:8)+53+0$*ACJIS(RR<"?PM+YT&SJBK'K_D$:_7SP;63)
MU*W%Z%(]<>&7=ZRTE*DGA__JM=3"ST,WX (IHX90_!EJ]-&MR$81O%!.G;0,
M.U>7M]=7/4P?W;OKH0!ESCP!CAAT+G$$]M&(3YY<OLH*[P$Z<Y7\+LWPR6 (
M4(.A^^@RA=X2,*FD01NA<V5;A0S=S/B*\)PF=RF+1] /^CS*U;2?Y#BK)<<'
MD1Q$,VK!L6E,N$OE/]W+,\T9N'HJIL)\=7S>N0SDJ&N"E+OKJU(RC(A^__GV
M$\K9'3@^J4!BX DNO6+)G\JIE^U(0!0%>7FE^<%"8VN'#Z"H8\X[&7->%1#E
MT1'OLS&I\\O56>^WVXON3M#$<U!L3_S?3*V&%8MU?X["M RH+!N36[#*QV74
MUV<CN3*GXHNI.JBEC!!F,$FAHL,R.NV)/HL"&3F3#2G3J2P@(W=B!/9(T1X;
MY?TDA;GQ^?#.+FX0LU[>N&6\7.3E$O/][)JQM>/*_,/EX=7PK.'Y?<+3:.@K
MP;.H_P[A=ID!W;N^/02?O/U-^WKK-T36Q%W#LX9G#<_O#9[?CY&[JM)[S_4B
M\)%:'Y/:/S#49S+#:NAO&?H_3][I.,Z=V4[_0Z*]F34+9726QDD,K^7J7)]%
MW[=N^E@V00W/&IXU/%>#I_UA5S+F!/,ANNDWSAO%L2?M! =)==8V1^U^*()G
M5Y2E1=G]KU]BEF[]8J<=).?7+"X>-[V$3TY_.F[V\T%T^O]02P,$%     @
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M&?J[/TI&:"_G0.@T;J0&_*M4_KLRWWOY.-+4P?I TD0#A$@YG)N'[4,'E$N
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M%4[?_OW-ZW$ZB=[^/U!+ 0(4 Q0    ( "* _5+HA9#<'1,  ,6O   1
M          "  0    !A;&5C+3(P,C$P-S(Y+FAT;5!+ 0(4 Q0    ( "*
M_5(^$ND2^ (  'D)   1              "  4P3  !A;&5C+3(P,C$P-S(Y
M+GAS9%!+ 0(4 Q0    ( "* _5*BY7CRKP4  +<T   5              "
M 7,6  !A;&5C+3(P,C$P-S(Y7VQA8BYX;6Q02P$"% ,4    "  B@/U2OTS/
M598$  #X)@  %0              @ %5'   86QE8RTR,#(Q,#<R.5]P<F4N
M>&UL4$L! A0#%     @ (H#]4C<K'!0I)   WUT! !<              ( !
M'B$  &%L96,M,C R,3 W,CEE>#DY7S$N:'1M4$L%!@     %  4 20$  'Q%
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
